Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk Warnings

Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk Warnings

Background: Baricitinib (BARI) or Tofacitinib (TOFA) were the first Janus Kinase Inhibitors (JAKi) to be marketed in rheumatoid arthritis (RA). Concerns regarding venous thromboembolism (VTE) risk have emerged during the past years. The aim of the study was to compare the baseline characteristics of...

Full description

Bibliographic Details
Main Authors: Cécile Philippoteaux, Valentine Deprez, Aurore Nottez, Emeline Cailliau, Eric Houvenagel, Xavier Deprez, Peggy Philippe, Tristan Pascart, René-Marc Flipo, Vincent Goëb, Jean-Guillaume Letarouilly
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Journal of Clinical Medicine
Subjects:
rheumatoid arthritis
JAK inhibitors
venous thromboembolic risk
tolerance
Online Access:https://www.mdpi.com/2077-0383/12/1/207

Internet

https://www.mdpi.com/2077-0383/12/1/207

Similar Items